سعر كوليروز 20مجم 21 قرص 2024

Cholerose 20 mg film-coated tablets containing rosuvastatin, marketed in Egypt by Marcyrl co.; pack of 21 tablets (3 strips of 7).

• Reduce risk of major adverse CV events in adults at increased riskPopulation: AdultsDailyMed (U.S. NLM)
• Adjunct to diet/exercise to reduce LDL-C in primary hypercholesterolemia; HeFH; HoFH; primary dysbetalipoproteinemia; hypertriglyceridemiaPopulation: Adults (pediatrics per HeFH/HoFH age criteria on US label)DailyMed (U.S. NLM)

• Most frequent adverse reactions (≥2%): headache, nausea, myalgia, asthenia, constipation.International label, same formulation · DailyMed (U.S. NLM)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. NLM)
• Hypersensitivity to rosuvastatin or any excipients.International label, same formulation · DailyMed (U.S. NLM)

• Myopathy and rhabdomyolysis: risk increases with age ≥65, uncontrolled hypothyroidism, renal impairment, interacting drugs, higher dose (especially 40 mg), and Asian ancestry. Discontinue if markedly elevated CK or myopathy suspected.International label, same formulation · DailyMed (U.S. NLM)
• Hepatic dysfunction: consider liver enzymes before initiation and as clinically indicated; discontinue if serious hepatic injury or jaundice occurs.International label, same formulation · DailyMed (U.S. NLM)
• Increases in HbA1c and fasting glucose have been reported with statins including rosuvastatin.International label, same formulation · DailyMed (U.S. NLM)

• CyclosporineMajorIncreases rosuvastatin exposure ~7-fold; do not exceed rosuvastatin 5 mg once daily. Management: Limit rosuvastatin to maximum 5 mg daily.DailyMed (U.S. NLM)
• GemfibrozilMajorIncreases myopathy/rhabdomyolysis risk and rosuvastatin exposure. Management: Avoid concomitant use; if unavoidable initiate 5 mg and do not exceed 10 mg once daily.DailyMed (U.S. NLM)
• WarfarinModerateRosuvastatin may increase INR. Management: Obtain INR before starting; monitor frequently until stable after initiation, titration or discontinuation.DailyMed (U.S. NLM)

• May cause fetal harm based on mechanism (decreases cholesterol synthesis). Discontinue when pregnancy is recognized, or consider ongoing therapeutic needs. Breastfeeding not recommended during treatment.International label, same formulation · DailyMed (U.S. NLM)

• Rosuvastatin: Competitive inhibition of HMG-CoA reductase reduces hepatic cholesterol synthesis and increases LDL-receptor expression.